La Jolla, CA, United States of America

Julius Rebek

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Cubist Pharmaceuticals, Incorporated. Active years: 1998.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Julius Rebek. Retrieved from https://idiyas.com/inventor/julius-rebek-52tj2seg

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 1998

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Mind of Julius Rebek

Introduction: Julius Rebek, a distinguished inventor based in La Jolla, CA, is renowned for his groundbreaking contributions to the field of chemistry and molecular biology.

Latest Patents: Julius Rebek holds several patents in the areas of organic chemistry and nanotechnology, focusing on novel methods for drug delivery and molecular synthesis.

Career Highlights: With a career spanning over four decades, Julius Rebek has held prominent positions at leading research institutions and universities, where he has spearheaded numerous research projects that have led to significant advancements in the field.

Collaborations: Throughout his career, Julius Rebek has collaborated with top scientists, researchers, and industry experts, fostering a culture of innovation and knowledge sharing that has resulted in cutting-edge discoveries and inventions.

Conclusion: Julius Rebek's relentless pursuit of innovation and his passion for pushing the boundaries of scientific knowledge have solidified his reputation as a visionary inventor in the realm of chemistry and molecular biology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…